Matsue-shi, Japan
Matsue-shi, Japan

Time filter

Source Type

Nagao S.,Hyogo Cancer Center | Nishio S.,Kurume University | Michimae H.,Kitasato University | Tanabe H.,Jikei University School of Medicine | And 6 more authors.
Gynecologic Oncology | Year: 2013

Objective The concept of "platinum sensitivity" has been widely applied in the management of recurrent ovarian cancer. This study aimed to evaluate the applicability of this concept to recurrent endometrial cancer. Patients and methods In this multicenter retrospective cohort study, the clinical data of patients with recurrent endometrial cancer, who had a history of receiving first-line platinum-based chemotherapy and who received second-line platinum-based chemotherapy at the time of recurrence between January 2005 and December 2009 were reviewed. Results A total of 262 patients from 30 centers with initial FIGO stage classifications of I (29), II (23), III (122), and IV (88) were enrolled. In total, 153 endometrioid adenocarcinomas, 34 serous adenocarcinomas, 17 clear cell adenocarcinomas, 36 carcinosarcomas, and 22 "other" tumors were documented. The response rates for patients with platinum-free intervals of < 6 months, 6-11 months, 12-23 months, and ≥ 24 months were 25%, 38%, 61%, and 65%, respectively. The median progression-free survival after second-line platinum-based chemotherapy for patients with platinum-free intervals of < 12 months and ≥ 12 months was 4.4 (95% confidence interval (CI) = 3.7-5.8) months and 10.3 (95% CI = 8.2-12.6) months, respectively (log-rank P < 0.0001), and the median overall survival was 13.8 (95% CI = 10.6-18.1) months and 40.9 (95% CI = 25.3-54.2) months, respectively (log-rank P < 0.0001). Conclusion Platinum-free interval is a predictor of response and survival after second-line platinum-based chemotherapy in patients with recurrent endometrial cancer. The concept of "platinum sensitivity" could be applicable to recurrent endometrial cancer. © 2013 Elsevier Inc.


Kanda N.,Kyoto University | Morimoto N.,Kyoto University | Takemoto S.,Matsue City Hospital | Ayvazyan A.A.,Kyoto University | And 4 more authors.
Annals of Plastic Surgery | Year: 2012

We have developed collagen/gelatin sponges (CGS) with a gelatin concentration of 10 wt% to sustain the release of basic fibroblast growth factor (bFGF). The objective of this study is to elucidate the efficacy of CGS impregnated with different concentrations of bFGF, using mouse skin defects. CGSs impregnated with normal saline solution (NSS) or bFGF solution (1, 7, 14, or 50 μg/cm) were implanted into full-thickness skin defects on the backs of mice. The wound area, neoepithelium length, and total area of newly formed capillaries in CGS were evaluated. The group of CGS with 7-μg/cm bFGF was significantly superior to the NSS group in all evaluated items. CGS impregnated with the appropriate dosage of bFGF accelerates dermis-like tissue formation 2 or 3 times earlier than existing artificial dermis. The combination of CGS and bFGF could solve the problem of the existing artificial dermis and be very promising for the treatment of skin defects. Copyright © 2012 Lippincott Williams &Wilkins.


Kanda N.,Kyoto University | Morimoto N.,Kyoto University | Ayvazyan A.A.,Kyoto University | Takemoto S.,Matsue City Hospital | And 5 more authors.
Journal of Tissue Engineering and Regenerative Medicine | Year: 2014

The objective of this study was to evaluate the ability of a scaffold, collagen-gelatin sponge (CGS), to release basic fibroblast growth factor (bFGF) in a sustained manner, using a pressure-induced decubitus ulcer model involving genetically diabetic mice. We confirmed that CGSs impregnated with a bFGF concentration of up to 50μg/cm2 were able to sustain the release of bFGF throughout their biodegradation. We prepared decubitus ulcers on diabetic mice. After debriding the ulcers, we implanted CGSs (diameter 8mm) impregnated with normal saline solution (NSS) or bFGF solution (7, 14, 28 or 50μg/cm2). At 1 and 2weeks after implantation, the mice were sacrificed and tissue specimens were obtained. The wound area, neoepithelium length and numbers and total area of newly formed capillaries were evaluated. The CGSs impregnated with NSS became infected and degraded, whereas the CGSs impregnated with 7 or 14μg/cm2 bFGF displayed accelerated dermis-like tissue formation and the CGSs impregnated with 14μg/cm2 bFGF produced significant improvements in the remaining wound area, neoepithelium length and numbers and total area of newly formed capillaries compared with the NSS group. No significant difference was observed between the NSS and 50μg/cm2 bFGF groups. CGSs impregnated with 7-14μg/cm2 bFGF accelerated wound healing, and an excess amount of bFGF did not increase the wound-healing efficacy of the CGSs. Our CGS is a scaffold that can release positively charged growth factors such as bFGF in a sustained manner and shows promise as a scaffold for skin regeneration. © 2012 John Wiley & Sons, Ltd.


Ayvazyan A.,Kyoto University | Morimoto N.,Kyoto University | Kanda N.,Kyoto University | Takemoto S.,Matsue City Hospital | And 4 more authors.
Journal of Surgical Research | Year: 2011

Background: We have developed a collagen-gelatin sponge (CGS) as a scaffold capable of the sustained release of bFGF to improve the healing process of the existing collagen scaffold. The aim of this study was to evaluate the efficacy of CGS impregnated with basic fibroblast growth factor (bFGF) in palatal wound healing in beagles. Materials and Methods: Four standardized 6 mm diameter full-thickness wounds were made in the palate of each dog and covered with CGS impregnated with normal saline or bFGF at concentrations of 1 μg/cm 2, 7 μg/cm 2 and 14 μg/cm 2. One and 2 wk after surgery, the wound area, neoepithelium length, thickness, area of regenerated submucosal tissue, and the number and total area of neoformed capillaries were evaluated. Results: Two weeks after implantation, wounds treated with bFGF 7 μg/cm 2 and 14 μg/cm 2 were completely epithelized, while the length of the neoformed epithelium was significantly longer in the 7 μg/cm 2 group. Groups impregnated with bFGF 7 μg/cm 2 and 14 μg/cm 2 showed promoted regeneration of submucosal tissue 2 wk later. The number and area of neoformed capillaries were significantly higher in the bFGF 7 μg/cm 2 group than in other groups. We conclude that palatal wound healing in the bFGF 7 μg/cm 2 group was promoted with good neovascularization and showed less contracture than other groups. Conclusions: Our new collagen-gelatin scaffold, CGS, impregnated with bFGF, could be a promising treatment to accelerate the regeneration of palatal mucosa. © 2011 Elsevier Inc. All rights reserved.


Itamochi H.,Tottori University | Oumi N.,Tottori University | Oishi T.,Tottori University | Shoji T.,Iwate Medical University | And 5 more authors.
International Journal of Clinical Oncology | Year: 2015

Background: Recent studies have shown that somatic mutations in the AT-rich interactive domain 1A (SWI-like) gene (ARID1A) are the most common genetic changes in clear cell carcinoma of the ovary (CCC). A gene mutation of ARID1A was found in approximately half of CCC cases, and led to absence of the encoded protein and inactivation of the putative tumor suppressor. Here, we investigated whether ARID1A could be a prognostic biomarker for this disease. Methods: We analyzed the protein expression of ARID1A in CCC from 112 patients by immunohistochemical staining, and evaluated the association of these molecular parameters with clinical outcome. Results: The loss of ARID1A expression was found in 39 % (44/112) of CCC, and was not associated with patient age, FIGO stage, and status of residual tumor. The 5-year survival rate for FIGO stage I or II patients with negative tumor expression of ARID1A was lower than those with positive tumor expression of ARID1A (74 % vs 91 %), but this difference was not observed in FIGO stage III or IV patients. Multivariable analysis revealed that ARID1A expression was an independent prognostic factor in FIGO stage I or II CCC patients. Conclusion: ARID1A may be a biomarker that is predictive of the outcome of FIGO stage I and II CCC. © 2015, Japan Society of Clinical Oncology.


Morimoto N.,Kyoto University | Takemoto S.,Kyoto University | Takemoto S.,Matsue City Hospital | Kawai K.,Kyoto University | And 3 more authors.
Annals of Plastic Surgery | Year: 2014

BACKGROUND: A bilayered artificial dermis is widely applied for skin defects. Its collagen sponge is biodegraded and replaced with dermis-like tissue after application. There is no reliable method for quantitatively evaluating the blood flow of artificial dermis. In this study, we used laser Doppler imaging to evaluate the perfusion of artificial dermis. MATERIALS AND METHODS: Twelve patients treated with artificial dermis and secondary skin grafting were included. We measured the perfusion unit just after application of artificial dermis, 1 week after, and before skin grafting. RESULTS: Secondary skin grafts of 6 patients took completely, and the others showed partial necrosis. Laser Doppler imaging could detect blood flow in the artificial dermis, and a significant difference was observed in perfusion units between the "complete take" group and "partial necrosis" group before grafting (P < 0.05). CONCLUSIONS: Laser Doppler imaging could be a useful and noninvasive technique for the evaluation of blood flow to the artificial dermis before grafting. Copyright © 2013 Lippincott Williams & Wilkins.


Mizumoto K.,Matsue City Hospital
Nishinihon Journal of Dermatology | Year: 2011

A 74-year-old woman had high fever, over 39°C, and itchy constant dark violet eruptions on her left upper arm and back. Her plasma level of ferritin was high. After further examination, she was diagnosed with adult Still's disease because her plasma level of interleukin (IL)-18 was notably high, and she was administered prednisolone at a daily dose of 30 mg. During the course of the disease, high fever recurred and she was administered a daily dose of 40 mg of prednisolone, which rapidly reduced the fever. After that the daily dose of prednisolone was gradually decreased to a daily dose of 5 mg. and she have had no recurrence through the 70th day after her first visit. Although this case did not fulfill Yamaguchi's diagnostic criteria of the adult Still's disease, with recent knowledge we were able to treat it rapidly because of the examination of the plasma level of IL-18. We considered the examination of inflammatory cytokines, such as IL-18, useful for the diagnosis of adult Still's disease.


Tatebe S.,Tottori University | Tatebe S.,Red Cross | Tsujitani S.,National Center for Global Health and Medicine | Nakamura S.,Tottori Prefectural Central Hospital | And 7 more authors.
Gastric Cancer | Year: 2014

Background: The Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer established oral S-1 administration for 1 year as the standard postoperative adjuvant chemotherapy for gastric cancer in Japan. We conducted a multicenter cooperative prospective study comparing daily and alternate-day S-1 administration as postoperative adjuvant therapy for gastric cancer. Methods: Patients with Stage II or III gastric cancer who underwent curative surgery were randomly assigned to receive standard daily S-1 administration [group A: 80-120 mg/day S-1 depending on body surface area (BSA); days 1-28 every 6 weeks for 1 year] or alternate-day administration (group B: 80-120 mg/day S-1 depending on BSA; alternate days for 15 months). Treatment completion rate was the primary endpoint, and relative dose intensity and safety, overall survival, and relapse-free survival (RFS) were secondary endpoints. Results: Seventy-three patients were enrolled. The treatment completion rate was 72.2 % in group A and 91.8 % in group B; the relative dose intensity was 67.5 % in group A and 81.2 % in group B; and compliance was better in group B. Digestive system adverse effects were less frequent in group B than in group A. Median follow-up time was 2.8 years; 3-year survival rate was 69.6 % in group A and 87.3 % in group B; and 3-year RFS rate was 76.4 % in group A and 73.1 % in group B. Conclusions: Our data show improved compliance and fewer adverse effects with alternate-day S-1 administration, which appears to be a more sustainable option for adjuvant chemotherapy for Stage II or III gastric cancer. © 2013 The International Gastric Cancer Association and The Japanese Gastric Cancer Association.


PubMed | Tottori University and Matsue City Hospital
Type: Journal Article | Journal: Yonago acta medica | Year: 2017

High-risk prostate cancer treatment has been controversial. Some high-risk prostate cancer patients fail to respond to radical prostatectomy only. Thus, we aimed to investigate the predictive factors for biochemical recurrence (BCR) and identify patients who could achieve sufficient therapeutic effect by radical prostatectomy only.Of 264 medical records reviewed, 141 low-intermediate-risk and 100 high-risk prostate cancer patients, excluding those who had received neoadjuvant hormone therapy, were analyzed. BCR was defined as the first increase in prostate-specific antigen levels ( 0.2 ng/mL), with levels not decreasing to undetectable limits, after radical prostatectomy. Log-rank test and Cox proportional hazards regression analyses were performed to determine the prognostic factors. We investigated the perioperative predictive factors for BCR and BCR-free survival rates, with the number of National Comprehensive Cancer Network (NCCN) high-risk factors for high-risk prostate cancer patients who underwent robot-assisted radical prostatectomy.Multivariate analyses showed that clinical T3 was significantly associated with BCR [hazard ratio (HR) = 4.052; 95% confidence interval (CI), 1.26-12.99; High-risk prostate cancer patients with 1 NCCN high-risk factor can be considered for robot-assisted radical prostatectomy treatment only.


PubMed | Matsue City Hospital, Tohoku University, Osaka University, Ashiya Municipal Hospital and 5 more.
Type: Journal Article | Journal: BMC palliative care | Year: 2017

The Care Evaluation Scale (CES1.0) was designed to allow bereaved family members to evaluate the structure and process of care, but has been associated with a high frequency of misresponses. The objective of this study was to develop a modified version of CES1.0 (CES2.0) that would eliminate misresponses while maintaining good reliability and validity.We conducted a cross-sectional questionnaire survey by mail in October 2013. The participants were bereaved family members of patients who died from cancer in seven institutions in Japan. All family members were asked to complete CES2.0, the short form CES1.0, items on overall care satisfaction, the Family Satisfaction with Advanced Cancer Care (FAMCARE) Scale, the Patient Health Questionnaire-9 (PHQ-9) and the Brief Grief Questionnaire (BGQ). To examine test-retest reliability, all participants were asked to complete a second CES2.0.Of 596 questionnaires sent, 461 (77%) were returned and 393 (66%) were analyzed. In the short form CES1.0, 17.1% of the responses were identified as misresponses. No misresponses were found in CES2.0. We identified 10 CES2.0 subscales similar to those in CES1.0 using exploratory factor analysis. Cronbachs alpha was 0.96, and the intraclass correlation coefficient was 0.83. Correlations were found between CES2.0 and overall satisfaction (r=0.83) and FAMCARE (r=0.58). In addition, total CES2.0 scores were negatively correlated with the PHQ-9 (r=-0.22) and BGQ (r=-0.10).These results suggest that CES2.0 eliminated misresponses associated with CES1.0 while maintaining good reliability and validity and greatly improving test-retest reliability.

Loading Matsue City Hospital collaborators
Loading Matsue City Hospital collaborators